OCTAPHARMA
Octapharma announces positive new clinical data in 66 previously treated patients (PTPs) with severe haemophilia A (HA) undergoing PK-guided personalized prophylaxis with Nuwiq® according to the NuPreviq Approach. Data from the NuPreviq study (GENA-21, NCT01863758) were published online in April 2017 as an Early View article in the internationally renowned medical journal, Haemophilia .
The NuPreviq study was initiated in August 2013 with the aim of developing a fully personalized service for HA patients undergoing prophylactic therapy. Octapharma’s aim is to improve patient treatment experiences by recognizing that no two HA patients are the same, therefore a “one size fits all ” approach to prophylaxis is not ideal. The NuPreviq study investigated a novel approach, allowing the Nuwiq® treatment regimen to be adapted to the specific needs of each individual patient. The NuPreviq Approach measures and profiles each individual patient’s pharmacokinetic response to treatment, which then allows the dosing of Nuwiq® to be personalized according to the specific circumstances of that patient.
The results of the study showed that this personalized prophylaxis approach was very effective at preventing bleeds, while reducing the frequency of dosing and the amount of Nuwiq® needed. Over 80% of patients did not experience a spontaneous bleed during the 6 months of personalized prophylaxis with Nuwiq® . More than half of the patients received infusions twice a week or less, and dose requirements were reduced by 7%. An ongoing extension study (GENA-21b, NCT02256917) will further evaluate the long-term efficacy and safety of personalized prophylaxis with Nuwiq® .
Larisa Belyanskaya, Head of IBU Haematology at Octapharma, said: “We are very excited by the results of the NuPreviq study and pleased that the GENA-21 study data are now available to the wider public in the specialist peer-reviewed publication, Haemophilia. The study shows that personalized prophylaxis with Nuwiq ® provides excellent bleeding protection, extension of the dosing interval for most patients, and a reduction in dose. These data further differentiate Nuwiq ® from other products on the market.”
Olaf Walter, Board Member at Octapharma, commented that “Octapharma’s principal motivation lies with providing dedicated service to our patients. Developing a custom care package which offers flexible FVIII therapy , truly personalized to suit their needs and lifestyle, has long been a goal of the company and we celebrate today this landmark publication of the extremely positive NuPreviq clinical data.”
Octapharma would like to thank everyone involved in the study, in particular the patients and their families, without whom this research would not be possible.
About GENA-21 and GENA-21b studies: The GENA-21 and GENA-21b studies, initiated in August 2013 and March 2015, respectively, are prospective, open-label, multicentre, Phase 3b studies assessing the safety and efficacy of PK-guided personalized prophylaxis with Nuwiq® in previously treated adult patients with severe HA. The studies are each conducted across 29 study locations worldwide.
About Nuwiq ® : Nuwiq® is a naturally long-acting, 4th generation rFVIII protein, produced in a human cell line without chemical modification or fusion with any other protein. Nuwiq® is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for the von Willebrand coagulation factor. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 PTPs (190 individuals) with severe HA, including 59 children. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding across all age groups of PTPs with haemophilia A in the EU, US, Canada, Australia, Latin America and Russia. Further worldwide submissions for Nuwiq® are planned.
About haemophilia A: Haemophilia A is an X-linked hereditary disorder caused by FVIII deficiency which, if left untreated, leads to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. FVIII replacement prophylactic treatment reduces the number of bleeding episodes and the risk of permanent joint damage. This disorder affects one in every 5,000 to 10,000 men worldwide. Globally, 75% of haemophilia cases are left undiagnosed or untreated. The development of neutralizing FVIII antibodies (FVIII inhibitors) against infused FVIII represents the most serious treatment complication. The cumulative risk of FVIII inhibitor development is reported to be currently up to 39%.
About Octapharma :
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood.
In 2016, the Group achieved €1.6 billion in revenue, an operating income of €383 million and invested €249 million to ensure future prosperity. Octapharma employs more than 7,100 people worldwide to support the treatment of patients in 113 countries with products across three therapeutic areas:
- Haematology (coagulation disorders)
- Immunotherapy (immune disorders)
- Critical care
Octapharma owns six state-of-the-art production facilities in Austria, France, Germany, Mexico and Sweden.
For more information visit www.octapharma.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170522005497/en/
Contact:
Octapharma AG
International Business Unit - Haematology
Olaf
Walter
Olaf.Walter@octapharma.com
or
Larisa
Belyanskaya
Larisa.Belyanskaya@octapharma.com
Tel:
+41 55 4512121
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biedermann Medtech Group Announces Transformation of U.S. Spine Market Approach and New Business Model28.8.2025 18:00:00 CEST | Press release
The Biedermann Medtech Group, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced a strategic transformation of its U.S. operations. Biedermann will expand its focus beyond product distribution to a broader platform of integrated services and solutions designed to reshape its U.S. business model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828746562/en/ As part of this transition, Biedermann Motech will discontinue to directly distribute its product lines of advanced solutions for spinal and extremity surgery in the U.S. market in the near future. This decision follows a comprehensive and detailed review of market dynamics and recent macro-economic developments. In the next phase of this transformation, Biedermann Motech will leverage its strategic partnership with intellectual property powerhouse and recognized innovation leader Biedermann Technolog
Stonebranch Named a Leader in the 2025 Gartner® Magic Quadrant™ for Service Orchestration and Automation Platforms (SOAPs)28.8.2025 17:49:00 CEST | Press release
Stonebranch recognized for the second consecutive year in the Leaders’ Quadrant for Completeness of Vision and Ability to Execute. Stonebranch, a leading provider of service orchestration and automation solutions, today announced that it has once again been positioned by Gartner as a Leader in the Magic Quadrant for Service Orchestration and Automation Platforms (SOAPs) for its offering, Universal Automation Center (UAC).1 The evaluation reflects Stonebranch’s completeness of vision and ability to execute. “We’re proud to be recognized as a Leader for the second year in a row,” said Giuseppe Damiani, CEO at Stonebranch. “We believe this recognition validates our strategy of enabling enterprises to embrace real-time, event-driven orchestration. Our customers rely on UAC to unify their automation landscape, scale operations securely, and drive digital transformation with confidence.” Stonebranch helps enterprises modernize IT automation across hybrid and multi-cloud environments with a n
Transition Industries Awards Techint E&C and Siemens Energy a FEED Contract for a 210 MW Electrolyzer Facility for the Pacifico Mexinol Project28.8.2025 15:00:00 CEST | Press release
Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and hydrogen facilities, has awarded Siemens Energy and Techint Engineering & Construction a Front-End Engineering Design (FEED) contract for an approximately 210 MW Elyzer P-300 electrolyzer facility as part of its 6,130 MT per day ultra-low carbon methanol Pacifico Mexinol project in Sinaloa, Mexico. The FEED study marks the next step in the expanding partnership between Transition Industries, Techint Engineering & Construction, and Siemens Energy, who intend to leverage their advanced technology and services to ensure the highest standards of efficiency and reliability in green hydrogen production. Under the terms of the FEED Agreement, Siemens Energy and Techint Engineering & Construction will provide an initial binding not-to-exceed Lump Sum Firm Price, followed by a final binding Lump Sum Turnkey Firm Price for the Engineering, Procurement and Construction (EPC) of the electrolyzer facility.
The Marriott Vacation Clubs™ Expands in Asia Pacific with New Resort in Khao Lak, Thailand and Growth in Bali and Shanghai28.8.2025 15:00:00 CEST | Press release
Marriott Vacation Club, Khao Lak Beach Resort marks the brand’s seventh vacation ownership resort in Asia Pacific, reinforcing growing demand across the region The Marriott Vacation Clubs™, a collection of vacation ownership brands under Marriott Vacations Worldwide Corporation, is expanding its presence in Asia Pacific with the opening of Marriott Vacation Club, Khao Lak Beach Resort in Thailand this August. The new resort is part of broader regional growth, that includes a new development at Marriott’s Enclave at Bali Nusa Dua Terrace and new apartments at Marriott’s Bali Nusa Dua Terrace, as well as the expansion of The Marriott Vacation Club’s marketing call center in Shanghai. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250827472037/en/ Marriott Vacation Club, Khao Lak Beach Resort provides scenic views of the Andaman Sea. Photograph depicts the JW Marriott, Khao Lak Resort & Spa. “Our continued investment in Asia Pa
Eaton and ChargePoint Launch Breakthrough Ultrafast DC V2X Chargers and Power Infrastructure to Accelerate the Future of EV Charging28.8.2025 14:33:00 CEST | Press release
Modular and DC Grid design can be deployed with 30% lower capex in a 30% smaller footprint while delivering up to a 30% reduction in ongoing operational costs, compared to other available solutionsJoint solution debuts at the RE+ trade show September 9, where Eaton will demonstrate broad capabilities advancing electrification and energy transition Intelligent power management company Eaton, together with ChargePoint, a leading provider of electric vehicle (EV) charging solutions, today announced an ultrafast charging architecture with end-to-end power infrastructure for public charging and fleets. ChargePoint Express Grid, powered by Eaton, is a vehicle-to-everything (V2X) capable solution that delivers up to 600kW of power for passenger EVs and can provide megawatt charging for heavy-duty commercial applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250827710125/en/ Eaton and ChargePoint announce ultrafast DC char
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom